Guangzhou Wondfo Biotech Co Ltd (300482) - Total Assets
Based on the latest financial reports, Guangzhou Wondfo Biotech Co Ltd (300482) holds total assets worth CN¥6.73 Billion CNY (≈ $985.42 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Guangzhou Wondfo Biotech Co Ltd (300482) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Guangzhou Wondfo Biotech Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 300482 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Guangzhou Wondfo Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Guangzhou Wondfo Biotech Co Ltd's total assets of CN¥6.73 Billion consist of 50.0% current assets and 50.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.0% |
| Accounts Receivable | CN¥774.19 Million | 11.7% |
| Inventory | CN¥280.58 Million | 4.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥275.93 Million | 4.2% |
| Goodwill | CN¥108.97 Million | 1.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300482 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangzhou Wondfo Biotech Co Ltd's current assets represent 50.0% of total assets in 2025, a decrease from 51.9% in 2011.
- Cash Position: Cash and equivalents constituted 7.0% of total assets in 2025, down from 12.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.
Guangzhou Wondfo Biotech Co Ltd Competitors by Total Assets
Key competitors of Guangzhou Wondfo Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
Guangzhou Wondfo Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.22 | 5.78 | 3.25 |
| Quick Ratio | 2.97 | 5.30 | 2.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.38 Billion | CN¥3.16 Billion | CN¥1.94 Billion |
Guangzhou Wondfo Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangzhou Wondfo Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.74 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -7.7% |
| Total Assets | CN¥6.60 Billion |
| Market Capitalization | $1.33 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Guangzhou Wondfo Biotech Co Ltd's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guangzhou Wondfo Biotech Co Ltd's assets decreased by 7.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guangzhou Wondfo Biotech Co Ltd (2011–2025)
The table below shows the annual total assets of Guangzhou Wondfo Biotech Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.60 Billion ≈ $966.03 Million |
-7.73% |
| 2024-12-31 | CN¥7.15 Billion ≈ $1.05 Billion |
+23.96% |
| 2023-12-31 | CN¥5.77 Billion ≈ $844.58 Million |
-8.40% |
| 2022-12-31 | CN¥6.30 Billion ≈ $922.05 Million |
+29.76% |
| 2021-12-31 | CN¥4.86 Billion ≈ $710.56 Million |
+12.77% |
| 2020-12-31 | CN¥4.31 Billion ≈ $630.12 Million |
+46.27% |
| 2019-12-31 | CN¥2.94 Billion ≈ $430.80 Million |
+9.38% |
| 2018-12-31 | CN¥2.69 Billion ≈ $393.85 Million |
+58.81% |
| 2017-12-31 | CN¥1.69 Billion ≈ $248.00 Million |
+68.51% |
| 2016-12-31 | CN¥1.01 Billion ≈ $147.17 Million |
+25.94% |
| 2015-12-31 | CN¥798.57 Million ≈ $116.86 Million |
+94.83% |
| 2014-12-31 | CN¥409.88 Million ≈ $59.98 Million |
+21.86% |
| 2013-12-31 | CN¥336.35 Million ≈ $49.22 Million |
+11.15% |
| 2012-12-31 | CN¥302.61 Million ≈ $44.28 Million |
+15.44% |
| 2011-12-31 | CN¥262.13 Million ≈ $38.36 Million |
-- |
About Guangzhou Wondfo Biotech Co Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more